{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:49:47Z","timestamp":1782427787915,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,25]]},"DOI":"10.7759\/cureus.111508","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:22:04Z","timestamp":1782426124000},"source":"Crossref","is-referenced-by-count":0,"title":["Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis"],"prefix":"10.7759","author":[{"given":"Augusto","family":"Carducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato S","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021, 398:1811-24. 10.1016\/S0140-6736(21)02188-7","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha R","year":"2023","unstructured":"Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr. 2023, 32:25-45. 10.7570\/jomes22067","journal-title":"J Obes Metab Syndr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka KP","year":"2013","unstructured":"Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci. 2013, 7:181. 10.3389\/fnins.2013.00181","journal-title":"Front Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan B","year":"2013","unstructured":"Finan B, Ma T, Ottaway N, et al.. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013, 5:209ra151. 10.1126\/scitranslmed.3007218","journal-title":"Sci Transl Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Reynolds GP","year":"2010","unstructured":"Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther. 2010, 125:169-79. 10.1016\/j.pharmthera.2009.10.010","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Peveler RC","year":"2008","unstructured":"Peveler RC, Branford D, Citrome L, et al.. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008, 22:98-103. 10.1177\/0269881107087346","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01867.x","article-title":"Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics","volume":"19","author":"Tonini M","year":"2004","unstructured":"Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004, 19:379-90. 10.1111\/j.1365-2036.2004.01867.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard FS","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MB, et al.. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020, 5:e140532. 10.1172\/jci.insight.140532","journal-title":"JCI Insight"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun B","year":"2022","unstructured":"Sun B, Willard FS, Feng D, et al.. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022, 119:e2116506119. 10.1073\/pnas.2116506119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0996","article-title":"Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance","volume":"151","author":"Garc\u00eda-Tornad\u00fa I","year":"2010","unstructured":"Garc\u00eda-Tornad\u00fa I, Ornstein AM, Chamson-Reig A, et al.. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology. 2010, 151:1441-50. 10.1210\/en.2009-0996","journal-title":"Endocrinology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470673-possible-attenuation-of-early-weight-loss-during-tirzepatide-therapy-in-a-patient-treated-with-levosulpiride-a-case-report-and-mechanistic-hypothesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:22:04Z","timestamp":1782426124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470673-possible-attenuation-of-early-weight-loss-during-tirzepatide-therapy-in-a-patient-treated-with-levosulpiride-a-case-report-and-mechanistic-hypothesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.111508","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}